This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

BioMarin to acquire Amicus in all-cash deal with equity value of $4.8 bn

( December 19, 2025, 14:32 GMT | Official Statement) -- MLex Summary: San Rafael, California-based BioMarin Pharmaceutical has agreed to acquire Princeton, New Jersey-based Amicus Therapeutics in an all-cash deal with an equity value of $4.8 billion. The merger is expected to enhance BioMarin's leadership in rare diseases, by giving it Galafold (migalastat) for Fabry disease and Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) for Pompe disease, adding two marketed, high-growth products with $599 million in revenue the past four quarters, according to a release.Statement follows in full. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login